Analyst consensus rating
Fennec Pharmaceuticals Analyst Rating: none
FENC is rated none by 6 analysts with a $15.67 target. As of 2026-08-26.
Direct answer
Fennec Pharmaceuticals's consensus rating is none.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $15.67.
Forecast evidence checked August 26, 2026.
Get free Fennec Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $12.17
- Average price target
- $15.67
- High price target
- $18.00
- Low price target
- $13.00
- Low target gap
- +6.8%
- Target upside
- +28.7%
- High target gap
- +47.9%
- Target range width
- 41.1%
- Consensus rating
- none
- Analysts
- 6
- Evidence date
- August 26, 2026
- Valid through
- September 2, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Fennec Pharmaceuticals?
Fennec Pharmaceuticals has a verified none consensus. The same dataset has an average price target of $15.67.
How far are Fennec Pharmaceuticals's low and high targets from the recorded price?
The low target implies +6.8%, while the high target implies +47.9%.
How many analysts are included in Fennec Pharmaceuticals's consensus?
The verified consensus includes 6 analysts.
How is Fennec Pharmaceuticals's target upside or downside calculated?
The average target of $15.67 is divided by the recorded price of $12.17, then one is subtracted to produce +28.7%. This does not guarantee a future return.
When was Fennec Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-08-26. The dataset is valid through 2026-09-02.